LONDON: Britain has approved GlaxoSmithKline (GSK) drug for use against Omicron, as it is safe and effective against this new variant, its manufacturer Glaxo said in a statement Thursday.
The antibody drug “is able to reduce the risk of hospitalisation and death in people with mild to moderate Covid-19 infection who are at an increased risk of developing severe disease,” said the Medicines and Healthcare Products Regulatory Agency (MHRA).
Preclinical data showed that the drug “retains activity against key mutations of the new Omicron SARS-CoV-2 variant,” said GSK.
“To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO),” it added.
More To Come